AstraZeneca (STU:ZEGA) Other Financing: €-449 Mil (TTM As of Mar. 2026)


STU:ZEGA AstraZeneca PLC STU:ZEGA
88 GF Score
Price €78.00
GF Value €78.43
! 2 Warning Signs
View Full Analysis

What is AstraZeneca Other Financing?

AstraZeneca STU:ZEGA +1.30% 88 Other Financing is €-449 Mil as of Mar. 2026. GuruFocus rates STU:ZEGA with a GF Score™ of 88/100 and a GF Value™ of €78.43. The stock has 2 warning signs investors should review.

AstraZeneca's Other Financing for the three months ended in Mar. 2026 was €19 Mil.

AstraZeneca's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was €-449 Mil.

AstraZeneca Other Financing Historical Data

* Premium members only.

The historical data trend for AstraZeneca's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AstraZeneca Other Financing Chart

AstraZeneca Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -157.53 -988.37 -812.46 -780.24 -59.78

AstraZeneca Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 96.20 -161.26 -78.38 -228.87 19.03
STU:ZEGA
88GF Score
AstraZeneca PLC STU:ZEGA
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AstraZeneca Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-449 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of €-449 Mil mean?
AstraZeneca (STU:ZEGA) has a Other Financing of €-449 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for AstraZeneca and its competitors.
Is AstraZeneca's Other Financing too high?
AstraZeneca's current Other Financing is €-449 Mil. Overall, AstraZeneca has a GF Score™ of 88/100, reflecting its overall financial health beyond just this single metric.
How does AstraZeneca's Other Financing compare to LLY and JNJ?
AstraZeneca's Other Financing of €-449 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Drug Manufacturers company?
A good Other Financing depends on the Drug Manufacturers industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for AstraZeneca and its competitors. AstraZeneca's current Other Financing is €-449 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AstraZeneca stock overvalued right now?
AstraZeneca (STU:ZEGA) has a current Other Financing of €-449 Mil. The stock's GF Value™ is €78.43, compared to a current price of €78.00 — trading 0.5% below its estimated fair value. The current Other Financing is €-449 Mil. AstraZeneca's overall GF Score™ is 88/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For AstraZeneca (STU:ZEGA), the current Other Financing is €-449 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AstraZeneca (STU:ZEGA) Overvalued in 2026?

Based on GuruFocus' analysis, AstraZeneca stock appears to be undervalued. The current stock price of €78.00 is trading 0.5% below its estimated GF Value™ of €78.43.

Key valuation signals for STU:ZEGA:

  • Other Financing: €-449 Mil
  • GF Value™: €78.43 vs. price of €78.00 (0.5% below fair value)
  • GF Score™: 88/100 with 2 warning signs

No single metric tells the full story. See the STU:ZEGA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AstraZeneca Business Description

Address 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
88GF Score

Get the complete analysis for STU:ZEGA

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€78.00
Price
€78.43
GF Value